Invention Grant
- Patent Title: Dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
-
Application No.: US15262268Application Date: 2016-09-12
-
Publication No.: US10092637B2Publication Date: 2018-10-09
- Inventor: Gwong-Jen J. Chang , Wayne D. Crill , Holly R. Hughes , Brent S. Davis
- Applicant: The United States of America as rep. by the Secretary of the Department of Health and Human Services
- Applicant Address: US DC Washington
- Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
- Current Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
- Current Assignee Address: US DC Washington
- Agency: Klarquist Sparkman, LLP
- Main IPC: A61K39/12
- IPC: A61K39/12 ; C07K14/005 ; C12N7/00 ; A61K39/00
Abstract:
Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.
Public/Granted literature
Information query
